subscribe
 

License agreement on human artificial lymph node technology

13th February 2018


ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins has announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial Lymph Node model was developed by ProBioGen as superior 3D-micro-organoid model for analysing substance effects on the human immune system in vitro.

Under the terms of the agreement the technology platform will be transferred to TEVA as a predictive tool to assist in the assessment of TEVA¹s biopharmaceutical drug candidates.

ProBioGen's Chief Scientific Officer, Dr Volker Sandig, commented: "With the complex, in vivo-like human Artificial Lymph Node model we have demonstrated effects which were impossible to see in conventional models, bridging the existing gap between animal models and first-in-man applications. We look much forward to this collaboration and the combined expertise on either side to develop the HuALN platform even further."





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe